Novel mechanism by which geniposide alleviates rheumatoid arthritis: Targeted inhibition of SphK1 negatively regulates S1P signaling, promotes HIF-1α acetylation-mediated degradation and blocks the VEGF-induced synovial angiogenesis.

BACKGROUND

Rheumatoid arthritis (RA) poses a significant health concern and profoundly affects patients' quality of life. Synovial angiogenesis, a key link in maintaining the formation of the RA pannus, is the fundamental reason for its prolonged treatment. Geniposide (GE) is an iridoid glycoside derived from Gardenia jasminoides Ellis (GJ) that shows promise as a treatment for RA, but its potential mechanism of regulating synovial angiogenesis remains unclear.

PURPOSE: This study aimed to elucidate the therapeutic effect of GE on RA angiogenesis and its potential underlying mechanism and specific target molecules.

METHODS

Synovial angiogenesis in CIA model rats were assessed by hematoxylin-eosin (HE) staining, infrared thermography, color Doppler flow imaging (CDFI), multi-color immunofluorescence (mIF) staining, Western blotting (WB) and relevance analysis. The CCK-8 and EdU assays, scratch tests, Transwell assays, tube formation assays, acetylation analysis, co-immunoprecipitation (Co-IP), laser scanning confocal microscopy (LSCM) and RT-qPCR were used to explore the mechanism of HDAC3/6 in negatively regulating HIF-1α acetylation-mediated degradation and their effect on the biological function of HUVECs. By constructing a SphK1-activated HUVEC model in vitro, the regulatory effects of S1P signaling on VEGF-induced synovial angiogenesis and GE treatment were clarified. Finally, the specific target of GE in the inhibiting of RA angiogenesis was confirmed through microscale thermophoresis (MST), molecular docking, molecular dynamics and cellular thermal shift assays (CETSAs).

RESULTS

The findings demonstrated that GE effectively ameliorated the pathological symptoms of CIA rats by suppressing synovial angiogenesis. Hypoxia-inducible factor 1α (HIF-1α), a transcription factor that governs oxygen homeostasis in vivo, contributed to synovial angiogenesis and promoted the regulatory effect of S1P on VEGF signaling. S1P signaling triggered HDAC3/6 expression via PI3K-Akt signaling, impeded HIF-1α acetylation-mediated degradation, increased VEGF and VEGFR2 transcription and translation and significantly influenced the biological functions of HUVECs. GE significantly inhibited the regulatory effect of S1P on VEGF signaling, thereby improving the abnormal biological functions of HUVECs. In addition, molecular target studies revealed a direct binding relationship between GE and SphK1, and the binding complex had a high stability and affinity. GE effectively inhibited RA synovial angiogenesis by targeting SphK1.

CONCLUSIONS

This study revealed that GE can suppress SphK1, leading to the decreased S1P/PI3K-Akt signaling, inhibition of HDAC3/6 activation, enhancement of HIF-1α acetylation-mediated degradation, and inhibition of S1P-mediated regulation of VEGF-induced synovial angiogenesis and alleviation of VECs dysfunction. These results suggest that preventing synovial angiogenesis could offer a novel approach for treating RA, with SphK1 emerging as a potential novel target for the diagnosis and treatment of RA in the future.